Нарушение мелатонинергической системы в патофизиологии диабетической энцефалопатии (обзор)

Автор: Быков Ю.В.

Журнал: Саратовский научно-медицинский журнал @ssmj

Статья в выпуске: 4 т.19, 2023 года.

Бесплатный доступ

Цель: провести анализ научной литературы для выявления основных патофизиологических механизмов нарушения мелатонинергической системы в формировании диабетической энцефалопатии и осветить возможную терапевтическую эффективность мелатонина (МЛТ). Методика написания обзора. Проанализированы 50 научных работ, размещенных в базах данных Cochrane Library, PubMed, eLibrary.ru, Medscape. Период электронного поиска - 2011-2023 гг., проводили с использованием комбинации ключевых слов: «diabetes mellitus», «melatonergic system», «melatonin» и «diabetic encephalopathy».

Апоптоз, воспаление, диабетическая энцефалопатия, мелатонин, оксидативный стресс, сахарный диабет

Короткий адрес: https://sciup.org/149144843

IDR: 149144843 | DOI: 10.15275/ssmj1904399

Список литературы Нарушение мелатонинергической системы в патофизиологии диабетической энцефалопатии (обзор)

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 (Suppl. 1): S81-S90. DOI:10.2337/dc14-S081
Xiong L, Liu S, Liu C, et al. The protective effects of melatonin in high glucose environment by alleviating autophagy and apoptosis on primary cortical neurons. Mol Cell Biochem. 2023; 478 (7): 1415-25. DOI:10.1007/s11010-022-04596-w
Быков Ю. В. Сахарный диабет I типа в педиатрической практике и поражения центральной нервной системы. Таврический медико-биологический вестник. 2020; 4 (23): 91-8.
Pourhanifeh МН, Hosseinzadeh A, Dehdashtian Е et al. Melatonin: New insights on its therapeutic properties in diabetic complications. Diabetol Metab Syndr 2020; 12: 30. DOI:10.1186 /s13098-020-00537-z
Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103 (2): 137-49. DOI:10.1016/j. diabres. 2013.11.002
Sadeghi A, Hami J, Razavi S, et al. The effect of diabetes mellitus on apoptosis in hippocampus: Cellular and molecular aspects. Int J Prev Med. 2016; 7: 57. DOI:10.4103/2008-7802.178531
Быков Ю.В. Оксидативный стресс и диабетическая энцефалопатия: патофизиологические механизмы. Современные проблемы науки и образования. 2022; 6-2: 39. DOI:10.17513/spno. 32314
Быков Ю.В., Батурин В. А. Диабетическая энцефалопатия при сахарном диабете в детском возрасте: патофизиология и клинические проявления (обзор). Саратовский научно-медицинский журнал. 2022; 18 (1): 46-9.
Ramos-Rodriguez JJ, Molina-Gil S, Ortiz-Barajas О, et al. Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models. PLoS One. 2014; 9 (2): e89229. DOI:10.1371/journal. pone. 0089229
Vieira LL, de Lima Soares RG, Da Silva Felipe SM, et al. Physiological targets for the treatment of diabetic encephalopathy. Cent Nerv Syst Agents Med Chem. 2017; 17 (1): 78-86. PMID: 27121380
Amin SN, Sharawy N, El Tablawy N, et al. Melatonin-Pretreated Mesenchymal Stem Cells Improved Cognition in a Diabetic Murine Model. Front Physiol. 2021; 12: 628107. DOI:10.3389/fphys.2021.628107
Kor Y, Geyikli I, Keskin M, Akan M. Preliminary study: Evaluation of melatonin secretion in children and adolescents with type 1 diabetes mellitus. Indian J Endocrinol Metab. 2014; 18 (4): 565-8. DOI:10.4103/2230-8210.137521
Shen QH, Li HF, Zhou XY, et al. Relation of serum melatonin levels to postoperative delirium in older patients undergoing major abdominal surgery. J Int Med Res. 2020; 48 (3): 300060520910642. DOI:10.1177/0300060520910642
Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol. 2019; 15 (2): 105-25. DOM 0.1038/S41574-018-0130-1
De Berardis D, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013; 14(6): 12458-83. DOI:10.3390/ijms140612458
Мичурина СВ., Васендин Д.В., Ищенко Д. Ю. Физиологические и биологические эффекты мелатонина: некоторые итоги и перспективы изучения. Российский физиологический журнал им. И.М. Сеченова. 2018; 104(3): 257-71.
Yu X, Li Z, Zheng H, et al. Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells. Cell Prolif. 2017; 50: e12323. DOI:10.1111/cpr.12323
Wu J, Tan Z, Li H, et al. Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5. J Pineal Res. 2021; 71 (3):e12765. DOI:10.1111/jpi.12765
Gurunathan S, Kang MH, Kim JH. Role and therapeutic potential of melatonin in the central nervous system and cancers. Cancers (Basel). 2020; 12 (6): 1567. DOI: 10.3390/cancers12061567
Arjunan A, Sah DK, Jung YD, Song J. Hepatic encepha-lopathy and melatonin. Antioxidants (Basel). 2022; 11 (5): 837. DOI: 10.3390/antiox11050837
Hsu MH, Chen YC, Sheen JM, et al. Melatonin prevented spatial deficits and increases in brain asymmetric dimethylargi-nine in young bile duct ligation rats. Neuroreport. 2018; 29: 541-6. DOI:10.1097/WNR. 0000000000000972
Cui Y, Yang M, Wang Y, et al. Melatonin prevents diabetes-associated cognitive dysfunction from microglia-mediated neuroinflammation by activating autophagy via TLR4/Akt/mTOR pathway. FASEB J. 2021; 35 (4): e21485. DOM0.1096/fj. 202002247 RR
Tchekalarova J, Nenchovska Z, Kortenska L, et al. Impact of melatonin deficit on emotional status and oxidative stress-induced changes in sphingomyelin and cholesterol level in young adult, mature, and aged rats. Int J Mol Sci. 2022; 23 (5): 2809. DOI:10.3390/ijms23052809
Morvaridzadeh M, Sadeghi E, Agah S, et al. Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis. Pharmacol Res. 2020; 161: 105210. DOI:10.1016/j.phrs.2020.105210
Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Mostavafi S, et al. Melatonin: An important anticancer agent in colorectal cancer. J Cell Physiol. 2020; 235 (2): 804-17. DOI:10.1002/jcp.29049
Maiocchi SL, Morris JC, Rees MD, Thomas SR. Regulation of the nitric oxide oxidase activity of myeloperoxidase by pharmacological agents. Biochem Pharmacol. 2017; (135): 90-115. DOI:10.1016/j.bcp.2017.03.016
Jangra A, Datusalia AK, Khandwe S, Sharma SS. Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: implication of oxidative stress — PARP pathway. Pharmacol Biochem Behav. 2013; (114-115): 43-51. DOI:10.1016/j. pbb. 2013.10.021
Hajam YA, Rai S, Roy A, et al. Repossession of brain complications in a streptozotocin induced diabetic rat by exogenous melatonin administration. Int J Zool Res. 2017; 13 (2): 64-73. DOI:10.3923/ijzr. 2017.64.73
Sharma C, Kim S, Nam Y, et al. Mitochondrial dysfunction asa driver of cognitive impairment in Alzheimer's disease. Int J Mol Sci. 2021; 22 (9): 4850. DOI:10.3390/ijms22094850
Reiter RJ, Ma Q, Sharma R, et al. Melatonin in mitochondria: Mitigating clear and present dangers. Physiology (Bethes-da). 2020; 35 (2): 86-95. DOI:10.1152/physiol. 00034.2019
Chen WR, Liu HB, Chen YD, et al. Melatonin attenuates myocardial ischemia/reperfusion injury by inhibiting autophagy via an AMPK/mTOR signaling pathway. Cell Physiol Biochem. 2018; 47 (5): 2067-76. DOI:10.1159/000491474
Ganie SA, Dar ТА, Bhat AH, et al. Melatonin: A potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Res. 2016; 19 (1): 21-40. DOI:10.1089/rej. 2015.1704
Muriach M, Flores-Bellver M, Romero FJ, Barcia JM. Diabetes and the brain: Oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev. 2014;2014:102158. DOI:10.1155/2014/102158
Chen L, Hu L, Zhao J, et al. Chotosan improves Ap 1-42-induced cognitive impairment and neuroinflammatory and apoptotic responses through the inhibition of TLR-4/NF-KB signaling in mice. Journal of Ethnopharmacology. 2016; 191: 398-407. DOI:10.1016/j.jep.2016.03.038
Duman TT, Aktas G, Atak BM, et al. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. African Health Sciences. 2019; 19 (1): 1602-6. DOI:10.4314/ahs. V19M.35
Sundberg I, Rasmusson AJ, Ramklint M, et al. Daytime melatonin levels in saliva are associated with inflammatory markers and anxiety disorders. Psychoneuroendocrinology. 2020; 112: 104514. DOI:10.1016/j.psyneuen.2019.104514
Ortiz F, Acuna-Castroviejo D, Doerrier C, et al. Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis. J Pineal Res. 2015; 58 (1): 34-49. DOI:10.1111 /jpi.12191
Permpoonputtana K, Govitrapong P. The antiinflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopa-mine SH-SY5Y cell lines. Neurotox Res. 2013; 23: 189-99. DOI:10.1007/sl 2640-012-9350-7
Zarezadeh M, Khorshidi M, Emami M, et al. Melatonin supplementation and pro-inflammatory mediators: A systematic review and meta-analysis of clinical trials. European Journal of Nutrition. 2020; 59 (5): 1803-13. DOI:10.1007/s00394-019-02123-0
Maher AM, Saleh SR, Elguindy NM, et al. Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2, 3-dioxygenase 1 expression. Life Sciences. 2020; (247): 117427. DOI:10.1016/j. Ifs.2020.117427
Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci. 2019; 20 (5): 1223. DOI:10.3390/ijms20051223
Yuan H, Wu G, Zhai X, et al. Melatonin and rapamycin attenuate isoflurane-induced cognitive impairment through inhibition of neuroinflammation by suppressing the mTOR signaling in the hippocampus of aged mice. Front Aging Neurosci. 2019; 11: 314. DOI:10.3389/fnagi.2019.00314
Yang B, Zhang LY, Chen Y, et al. Melatonin alleviates intestinal injury, neuroinflammation and cognitive dysfunction caused by intestinal ischemia/reperfusion. Int Immunopharma-col. 2020; 85: 106596. DOI:10.1016/j.intimp.2020.106596
Bloemer J, Bhattacharya S, Amin R, Suppiramaniam V. Impaired insulin signaling and mechanisms of memory loss. Prog Mol Biol Transl Sci. 2014; 121: 413-49. DOI:10.1016/B978-0-12-800101-1.00013-2
Sharma S, Singh H, Ahmad N, et al. The role of melatonin in diabetes: Therapeutic implications. Arch Endocrinol Metab. 2015; 59 (5): 391-9. DOI:10.1590/2359-3997000000098
Wongchitrat P, Lansubsakul N, Kamsrijai U, et al. Melatonin attenuates the high-fat diet and streptozotocin-induced reduction in rat hippocampal neurogenesis. Neurochem Int. 2016; 100: 97-109. DOI:10.1016/j.neuint.2016.09.006
Kamsrijai U, Wongchitrat P, Nopparat C, et al. Melatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats. Neurochem Int. 2020; 132: 104601. DOM 0.1016/j. neuint.2019.104601
Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheim-ers Dis. 2014; 42 Suppl. 3: S125-52. DOM 0.3233/JAD-132738
Amer ME, Othamn Al, El-Missiry MA. Melatonin ameliorates diabetes-induced brain injury in rats. Acta Histochem. 2021; 123(2): 151677. DOI:10.1016/j.acthis.2020.151677
Carrasco C, Rodriguez AB, Pariente JA. Melatonin as a stabilizer of mitochondrial function: Role in diseases and aging. Turk J Biol. 2015; 39(6): 822-31. DOI:10.3906/biy-1504-26

Еще

Статья обзорная